COLOMBO NICOLETTA

Fumagalli, D., Jayraj, A., Olearo, E., Capasso, I., Hsu, H., Tzur, Y., et al. (2025). Erratum to ‘Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer’ [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101664] (International Journal of Gynecological Cancer (2025) 35(3), (S1048891X25001896), (10.1016/j.ijgc.2025.101664)) [Altro] [10.1016/j.ijgc.2025.101952]. Detail

Vergote, I., Copeland, L., Van Gorp, T., Laenen, A., Scambia, G., Thaker, P., et al. (2025). Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study. EUROPEAN JOURNAL OF CANCER, 219(26 March 2025) [10.1016/j.ejca.2025.115306]. Detail

Franciosa, G., Nieddu, V., Battistini, C., Caffarini, M., Lupia, M., Colombo, N., et al. (2025). Quantitative Proteomics and Phosphoproteomics Analysis of Patient-Derived Ovarian Cancer Stem Cells. MOLECULAR & CELLULAR PROTEOMICS, 24(5) [10.1016/j.mcpro.2025.100965]. Detail

De Vitis, L., Schivardi, G., Delfrati, S., Biffi, B., Viscardi, A., Rosanu, M., et al. (2025). The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 35(1) [10.1016/j.ijgc.2024.100024]. Detail

Oza, A., Lisyanskaya, A., Fedenko, A., De Melo, A., Shparyk, Y., Rakhmatullina, I., et al. (2025). Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial. THE LANCET ONCOLOGY, 26(2), 249-264 [10.1016/S1470-2045(24)00674-0]. Detail